儿童患者与单一物质暴露相关的癫痫发作:一项15年回顾性研究

IF 3.3
Chia Ming Chang, Christopher P Holstege, Conner T McDonald, Sandra H Nixon, Rita Farah
{"title":"儿童患者与单一物质暴露相关的癫痫发作:一项15年回顾性研究","authors":"Chia Ming Chang, Christopher P Holstege, Conner T McDonald, Sandra H Nixon, Rita Farah","doi":"10.1080/15563650.2025.2519321","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the trends, demographics, outcomes, and substances associated with single-substance exposures associated with in seizures in pediatric patients over 15 years.</p><p><strong>Methods: </strong>This retrospective study of the National Poison Data System<sup>®</sup> was conducted from 2009 to 2023, including pediatric patients (<20 years) who experienced seizures as a clinical effect associated with single-substance exposures. Cases with single seizures, multi/discrete seizures, or status epilepticus were included. Trends in annual frequency, seizure rates (per 100,000 exposures), and substances associated with seizures were examined.</p><p><strong>Results: </strong>Thirty thousand nine hundred and eighty-five patients with single-substance exposures associated with seizures were identified, including 1,712 cases of status epilepticus. Reports to poison centers saw an increase in cases with seizures from 1,418 in 2009 to 2,749 in 2023. The seizure rate increased from 88 to 237 per 100,000 exposures. Patients aged 13-19 years accounted for the majority of cases (66.9%), followed by aged 0-5 years (24.0%) and 6-12 years (9.1%). Diphenhydramine and bupropion were the leading contributors, with diphenhydramine-related seizures increasing from 85 in 2009 to 404 in 2023 and bupropion cases rising from 162 in 2013 to 431 in 2023. Moderate and major effects were reported in 41.9% and 35.8% of cases, respectively, with nearly half (47.8%) requiring admission to critical care units.</p><p><strong>Discussion: </strong>The current study shows an increase in substance-related pediatric seizures, particularly among adolescents and females. The significant need for critical care in nearly half of these cases shows the severity and potential long-term impact of these exposures.</p><p><strong>Conclusions: </strong>Pediatric seizures associated with single-substance exposures are on the rise, driven primarily by diphenhydramine and bupropion. This trend highlights the need for targeted prevention strategies to reduce the burden of toxic exposures and safeguard the well-being of pediatric populations.</p>","PeriodicalId":520593,"journal":{"name":"Clinical toxicology (Philadelphia, Pa.)","volume":" ","pages":"562-569"},"PeriodicalIF":3.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Seizures associated with single substance exposures in pediatric patients: a 15-year retrospective study.\",\"authors\":\"Chia Ming Chang, Christopher P Holstege, Conner T McDonald, Sandra H Nixon, Rita Farah\",\"doi\":\"10.1080/15563650.2025.2519321\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This study aims to evaluate the trends, demographics, outcomes, and substances associated with single-substance exposures associated with in seizures in pediatric patients over 15 years.</p><p><strong>Methods: </strong>This retrospective study of the National Poison Data System<sup>®</sup> was conducted from 2009 to 2023, including pediatric patients (<20 years) who experienced seizures as a clinical effect associated with single-substance exposures. Cases with single seizures, multi/discrete seizures, or status epilepticus were included. Trends in annual frequency, seizure rates (per 100,000 exposures), and substances associated with seizures were examined.</p><p><strong>Results: </strong>Thirty thousand nine hundred and eighty-five patients with single-substance exposures associated with seizures were identified, including 1,712 cases of status epilepticus. Reports to poison centers saw an increase in cases with seizures from 1,418 in 2009 to 2,749 in 2023. The seizure rate increased from 88 to 237 per 100,000 exposures. Patients aged 13-19 years accounted for the majority of cases (66.9%), followed by aged 0-5 years (24.0%) and 6-12 years (9.1%). Diphenhydramine and bupropion were the leading contributors, with diphenhydramine-related seizures increasing from 85 in 2009 to 404 in 2023 and bupropion cases rising from 162 in 2013 to 431 in 2023. Moderate and major effects were reported in 41.9% and 35.8% of cases, respectively, with nearly half (47.8%) requiring admission to critical care units.</p><p><strong>Discussion: </strong>The current study shows an increase in substance-related pediatric seizures, particularly among adolescents and females. The significant need for critical care in nearly half of these cases shows the severity and potential long-term impact of these exposures.</p><p><strong>Conclusions: </strong>Pediatric seizures associated with single-substance exposures are on the rise, driven primarily by diphenhydramine and bupropion. This trend highlights the need for targeted prevention strategies to reduce the burden of toxic exposures and safeguard the well-being of pediatric populations.</p>\",\"PeriodicalId\":520593,\"journal\":{\"name\":\"Clinical toxicology (Philadelphia, Pa.)\",\"volume\":\" \",\"pages\":\"562-569\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical toxicology (Philadelphia, Pa.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/15563650.2025.2519321\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical toxicology (Philadelphia, Pa.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15563650.2025.2519321","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本研究旨在评估15岁以上儿科患者癫痫发作的趋势、人口统计、结果和与单一物质暴露相关的物质。方法:对2009年至2023年的国家毒物数据系统®进行回顾性研究,包括儿科患者(结果:确定了30,985例与癫痫发作相关的单一物质暴露患者,其中包括1,712例癫痫持续状态。中毒中心收到的报告显示,癫痫发作病例从2009年的1418例增加到2023年的2749例。缉获率从每100,000次接触88次增加到237次。13-19岁患者占多数(66.9%),其次为0-5岁(24.0%)和6-12岁(9.1%)。苯海拉明和安非他酮是主要因素,与苯海拉明相关的癫痫发作从2009年的85例增加到2023年的404例,安非他酮从2013年的162例增加到2023年的431例。分别有41.9%和35.8%的病例报告了中度和重度影响,其中近一半(47.8%)需要入住重症监护病房。讨论:目前的研究显示与药物相关的儿童癫痫发作增加,特别是在青少年和女性中。这些病例中有近一半需要重症监护,这表明这些暴露的严重性和潜在的长期影响。结论:与单一物质暴露相关的儿童癫痫发作呈上升趋势,主要由苯海拉明和安非他酮驱动。这一趋势突出表明,需要制定有针对性的预防战略,以减少接触有毒物质的负担,保障儿科人群的福祉。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Seizures associated with single substance exposures in pediatric patients: a 15-year retrospective study.

Introduction: This study aims to evaluate the trends, demographics, outcomes, and substances associated with single-substance exposures associated with in seizures in pediatric patients over 15 years.

Methods: This retrospective study of the National Poison Data System® was conducted from 2009 to 2023, including pediatric patients (<20 years) who experienced seizures as a clinical effect associated with single-substance exposures. Cases with single seizures, multi/discrete seizures, or status epilepticus were included. Trends in annual frequency, seizure rates (per 100,000 exposures), and substances associated with seizures were examined.

Results: Thirty thousand nine hundred and eighty-five patients with single-substance exposures associated with seizures were identified, including 1,712 cases of status epilepticus. Reports to poison centers saw an increase in cases with seizures from 1,418 in 2009 to 2,749 in 2023. The seizure rate increased from 88 to 237 per 100,000 exposures. Patients aged 13-19 years accounted for the majority of cases (66.9%), followed by aged 0-5 years (24.0%) and 6-12 years (9.1%). Diphenhydramine and bupropion were the leading contributors, with diphenhydramine-related seizures increasing from 85 in 2009 to 404 in 2023 and bupropion cases rising from 162 in 2013 to 431 in 2023. Moderate and major effects were reported in 41.9% and 35.8% of cases, respectively, with nearly half (47.8%) requiring admission to critical care units.

Discussion: The current study shows an increase in substance-related pediatric seizures, particularly among adolescents and females. The significant need for critical care in nearly half of these cases shows the severity and potential long-term impact of these exposures.

Conclusions: Pediatric seizures associated with single-substance exposures are on the rise, driven primarily by diphenhydramine and bupropion. This trend highlights the need for targeted prevention strategies to reduce the burden of toxic exposures and safeguard the well-being of pediatric populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信